Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

UMN Pharma Receives Investment From Tokyo Engineering Company

This article was originally published in PharmAsia News

Executive Summary

Akita-based UMN Pharma signed a contract with Tokyo-based IHI Plant Engineering, which will design manufacturing equipment for UMN's new avian flu vaccine production plant in Akita Prefecture in early 2009. The total contract's estimated value is ¥2 billion. To strengthen the cooperation with UMN Pharma, IPEC invested ¥200 million and acquired 2 percent of UMN shares. IPEC also plans to further invest ¥200 million in the bioventure company. (Click here for more - Japanese language

Table

View full table

Tags:
Latest Headlines

Obesity Gold Rush To Drive Significant Spending Growth Through Decade, IQVIA Says

With Vertex Pain Drug Filed At FDA, Commercial Ramp Is Under Way

Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases

BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024

See All
UsernamePublicRestriction

Register

SC069392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By